US FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment
GSK•The US FDA approved GSK's hepatitis B drug Hibsago, which can keep the virus under control after patients stop treatment. It is the first FDA-approved antisense oligonucleotide for chronic hepatitis B.
1. FDA approves Hibsago
The US FDA approved GSK's Hibsago, chemically known as bepirovirsen, for hepatitis B. The drug offers patients a way to keep the virus under control after stopping treatment and is the first FDA-approved antisense oligonucleotide for chronic hepatitis B.
